Navigation Links
John Theurer Cancer Center brings leading experts for its Ninth Annual Neuro-Oncology Symposium
Date:5/9/2013

Hackensack NJ (May 9, 2013) - John Theurer Cancer Center at Hackensack University Medical Center, one of the nation's top 50 cancer centers, will host its Ninth Annual Neuro-Oncology Symposium on Friday, May 17th from 8:00am-1:00pm. Experts from MD Anderson, Memorial Sloan Kettering Cancer Center, Penn State Milton S. Hershey Medical Center, and the Cleveland Clinic will present advances in multidisciplinary care for cancers of the central nervous system.

"Our guest speakers are among the nation's leaders in neuro-oncology," said Samuel Goldlust, M.D., Co-Chief of the Brain and Spine Institute at John Theurer Cancer Center. "They will present their perspectives on the latest neurosurgical and medical treatment options and those on the horizon."

This program is intended for all healthcare providers who care for patients with central nervous system (CNS) cancers. At the conclusion of the program participants will be able to identify current standards of care, describe benchmark data that led to current treatment paradigms, and review recent advances in multidisciplinary care and the potential impact on survival and quality of life.

"This is an opportunity for healthcare professionals in the tristate area involved in the treatment of CNS cancers to learn about advances in research that shape the way we care for patients. " said George Kaptain, M.D., Co-Chief of the Brain and Spine Institute.

Featured speakers and their presentations include:

  • John DeGroot, M.D., Associate Professor, Department of Neuro-Oncology, University of Texas, M.D. Anderson Cancer Center: Anti-Angiogenic Therapy: Efficacy and Mechanisms of Resistance
  • Michael J. Glantz, M.D., Professor Neurosurgery, Medicine and Neurology, Penn State Milton S. Hershey Medical Center: Neoplastic Meningitis: How Can We Stop Snatching Defeat From The Jaws of Victory?
  • Jason T. Huse, M.D., Ph.D., Assistant Attending, Department of Pathology, Memorial Sloan-Kettering Cancer Center: The Emerging Molecular Foundations of Diffuse Gliomas
  • Michael Vogelbaum, M.D., Ph.D., Associate Director, Brain Tumor and Neuro-Oncology Center, Cleveland Clinic Foundation: Surgery for Gliomas: How Far Should We Go?

"It's an exciting time for neuro-oncology at our Brain and Spine Institute," said Chief Emeritus Mark S. Pascal, M.D. "Recently we have seen tremendous programmatic growth, including in our Gamma Knife radiosurgery center, robust clinical trial program, and dedicated support services for neuro-oncology patients."

The conference will be held at John Theurer Cancer Center, 92 Second Street, Hackensack, NJ 07601. HackensackUMC designates this educational activity for a maximum of 4.0 AMA PRA Category 1 Credit(s), physicians should only claim credits commensurate with the extent of their participation in the activity. This conference is complimentary but advanced registration is required. To register or for more information, please contact Maryann V. Lederhilger at 551-996-1162 or mlederhilger@HackensackUMC.org.

"Oncology is moving at an accelerated pace," said Andre Goy, M.D., M.S., Chairman and Director, Chief of Lymphoma, John Theurer Cancer Center and Chief Science Officer and Director of Research and Innovation at Regional Cancer Care Associates. "We believe it is more important than ever to help physicians and healthcare professional stay up to date with the latest research and treatment best practices."

"John Theurer Cancer Center is committed to helping healthcare professionals gain access to, and knowledge of, the latest advancements in cancer care, and we are proud to offer continuing education programs like the neuro-oncology symposium to help fulfill this goal," said Andrew L. Pecora, M.D., F.A.C.P., C.P.E., Chief Innovations Officer, Professor, and Vice President of Cancer Services and President of Regional Cancer Care Associates.


'/>"/>

Contact: Amy Leahing
aleahing@p4strategy.com
646-476-3845
John Theurer Cancer Center
Source:Eurekalert

Related medicine news :

1. John Theurer Cancer Center hosts first Womens Oncology Conference
2. John Theurer Cancer Center to present 37 studies at the 2012 ASH Annual Meeting
3. John Theurer Cancer Center researchers shed light on new multiple myeloma therapy
4. Experts from John Theurer Cancer Center to participate in the AAMDSIF Patient and Family Conference
5. John Theurer Cancer Center hosting 8th Annual Neuro-Oncology Symposium
6. Research finds identifies social needs of young people with cancer
7. Popular diabetes drug does not improve survival rates after cancer: Study
8. Your immune system: On surveillance in the war against cancer
9. Fun and friends help ease the pain of breast cancer
10. Missouri Man Alleges Five Years of Actos Use Caused his Bladder Cancer; Parker Waichman LLP Files Lawsuit on Victim’s Behalf
11. Just How Might Exercise Lower Breast Cancer Risk?
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2016)... ... December 03, 2016 , ... The Lymphoma Research Foundation ... research and serving the lymphoma community through a comprehensive series of education programs, ... Event in New York City, with long-time partners The Paul Foundation, on November ...
(Date:12/4/2016)... Aliso Viejo, California (PRWEB) , ... December 04, ... ... self-animating lower third presets that have new attractive animation styles with unique displacement ... Pro3rd Displace features 30 pre-animated lower third designs. Choose from a variety of ...
(Date:12/2/2016)... , ... December 02, 2016 , ... Lori G. ... Traurig, LLP’s Atlanta office, will speak at the American Conference Institute’s 21st Drug ... Traurig is also a Lead Sponsor of the conference. , Cohen, who chairs the ...
(Date:12/2/2016)... ... December 02, 2016 , ... Advanced Inc., a leading provider of ... Bice, CPA, MBA to serve as Advanced Inc.’s Chief Financial Officer, effective December 1, ... Jason brings extensive financial and operational leadership experience to Advanced Inc. He began his ...
(Date:12/2/2016)... PA (PRWEB) , ... December 02, 2016 , ... With ... struggling through rehabilitation of an injury, patients must find the one that works for ... his pain, he created a machine that worked and decided to share it with ...
Breaking Medicine News(10 mins):
(Date:12/4/2016)...   Pairnomix, LLC, a genetic research company and ... the White House, today announced that findings from its first ... candidate therapies for a patient with epileptic encephalopathy caused by ... at the 70 th Annual Meeting of the ... , December 2-6, 2016.  Pairnomix, unique process involves ...
(Date:12/4/2016)... EAST HANOVER, N.J. , Dec. 3, 2016 /PRNewswire/ ... SEG101 (crizanlizumab, formerly SelG1), an anti-P-selectin antibody, reduced the ... by 45.3% compared to placebo (1.63 vs 2.98, p=0.010) ... Novartis today announced that the data are being featured ... American Society of Hematology (ASH) Annual Meeting and ...
(Date:12/4/2016)... Dec. 3, 2016  Findings from a Novartis ... CTL019, an investigational chimeric antigen receptor T cell ... young adult patients with B-cell acute lymphoblastic leukemia ... session at the 58th American Society of Hematology ... p.m.). The global Phase II study found that ...
Breaking Medicine Technology: